S&P 500   4,596.29 (-1.27%)
DOW   34,662.39 (-1.35%)
QQQ   394.75 (-1.24%)
AAPL   163.98 (+2.33%)
MSFT   331.63 (-1.49%)
FB   327.48 (-3.12%)
GOOGL   2,854.57 (-1.93%)
AMZN   3,515.38 (-1.30%)
TSLA   1,138.99 (+0.18%)
NVDA   325.36 (-2.52%)
BABA   127.27 (-3.30%)
NIO   39.21 (-3.09%)
CGC   10.48 (-5.24%)
AMD   157.83 (-2.52%)
GE   95.42 (-3.03%)
MU   85.20 (-1.09%)
T   22.75 (-4.77%)
F   19.26 (-2.08%)
DIS   144.48 (-2.25%)
ACB   6.25 (-2.95%)
AMC   34.10 (-7.44%)
PFE   54.31 (+3.65%)
BA   195.75 (-1.39%)
S&P 500   4,596.29 (-1.27%)
DOW   34,662.39 (-1.35%)
QQQ   394.75 (-1.24%)
AAPL   163.98 (+2.33%)
MSFT   331.63 (-1.49%)
FB   327.48 (-3.12%)
GOOGL   2,854.57 (-1.93%)
AMZN   3,515.38 (-1.30%)
TSLA   1,138.99 (+0.18%)
NVDA   325.36 (-2.52%)
BABA   127.27 (-3.30%)
NIO   39.21 (-3.09%)
CGC   10.48 (-5.24%)
AMD   157.83 (-2.52%)
GE   95.42 (-3.03%)
MU   85.20 (-1.09%)
T   22.75 (-4.77%)
F   19.26 (-2.08%)
DIS   144.48 (-2.25%)
ACB   6.25 (-2.95%)
AMC   34.10 (-7.44%)
PFE   54.31 (+3.65%)
BA   195.75 (-1.39%)
S&P 500   4,596.29 (-1.27%)
DOW   34,662.39 (-1.35%)
QQQ   394.75 (-1.24%)
AAPL   163.98 (+2.33%)
MSFT   331.63 (-1.49%)
FB   327.48 (-3.12%)
GOOGL   2,854.57 (-1.93%)
AMZN   3,515.38 (-1.30%)
TSLA   1,138.99 (+0.18%)
NVDA   325.36 (-2.52%)
BABA   127.27 (-3.30%)
NIO   39.21 (-3.09%)
CGC   10.48 (-5.24%)
AMD   157.83 (-2.52%)
GE   95.42 (-3.03%)
MU   85.20 (-1.09%)
T   22.75 (-4.77%)
F   19.26 (-2.08%)
DIS   144.48 (-2.25%)
ACB   6.25 (-2.95%)
AMC   34.10 (-7.44%)
PFE   54.31 (+3.65%)
BA   195.75 (-1.39%)
S&P 500   4,596.29 (-1.27%)
DOW   34,662.39 (-1.35%)
QQQ   394.75 (-1.24%)
AAPL   163.98 (+2.33%)
MSFT   331.63 (-1.49%)
FB   327.48 (-3.12%)
GOOGL   2,854.57 (-1.93%)
AMZN   3,515.38 (-1.30%)
TSLA   1,138.99 (+0.18%)
NVDA   325.36 (-2.52%)
BABA   127.27 (-3.30%)
NIO   39.21 (-3.09%)
CGC   10.48 (-5.24%)
AMD   157.83 (-2.52%)
GE   95.42 (-3.03%)
MU   85.20 (-1.09%)
T   22.75 (-4.77%)
F   19.26 (-2.08%)
DIS   144.48 (-2.25%)
ACB   6.25 (-2.95%)
AMC   34.10 (-7.44%)
PFE   54.31 (+3.65%)
BA   195.75 (-1.39%)
NASDAQ:QLGN

Qualigen Therapeutics Earnings Date, Estimates, & History

$1.43
-0.15 (-9.49%)
(As of 11/30/2021 01:52 PM ET)
Add
Compare
Today's Range
$1.34
$1.65
50-Day Range
$0.94
$2.56
52-Week Range
$0.93
$4.66
Volume
220,211 shs
Average Volume
2.47 million shs
Market Capitalization
$41.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.6

Earnings Summary

Upcoming
Earnings Date
Feb. 21
Estimated

Actual EPS
(Nov. 15)
-$0.10
Beat By $0.10

Consensus EPS
(Nov. 15)
-$0.20

Last Year's Q4 EPS
(11/19/2020)
-$0.41

Skip Charts & View Estimated and Actual Earnings Data

Qualigen Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Qualigen Therapeutics Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Qualigen Therapeutics (NASDAQ:QLGN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20211$0.26$0.26$0.26
Q3 20211($0.12)($0.12)($0.12)
Q4 20211($0.13)($0.13)($0.13)
20213$0.01$0.01$0.01
Q2 20221($0.21)($0.21)($0.21)
Q3 20221($0.23)($0.23)($0.23)

QLGN Earnings Information

Qualigen Therapeutics last issued its earnings results on November 15th, 2021. The reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.10. The firm earned $1.16 million during the quarter, compared to the consensus estimate of $1.50 million. Qualigen Therapeutics has generated $0.00 earnings per share over the last year. Qualigen Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 21st, 2022 based off prior year's report dates.

Qualigen Therapeutics (NASDAQ:QLGN) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
2/21/2022
(Estimated)
        
11/15/20219/30/2021($0.20)($0.10)+$0.10($0.10)$1.50 million$1.16 million
8/17/20216/30/2021($0.18)($0.18)($0.18)$1.12 million
5/14/2021Q4 2021($0.21)($0.21)($0.29)$1.30 million$1.90 million
11/19/2020Q2($0.10)($0.41)($0.31)$0.03$1.40 million$0.84 million
8/14/2020Q2 2020($0.27)($0.27)$1.58$0.90 million
5/1/2020Q1 2020($1.25)($1.25)($1.25)
3/31/2020Q4 2019($1.25)($1.25)($1.25)
11/13/2019Q3 2019($5.75)($5.75)($5.75)
8/14/2019Q2 2019($11.25)($7.75)+$3.50($7.75)
5/14/2019Q1 2019($17.75)($14.50)+$3.25($14.50)
3/29/2019Q4 2018($41.50)($41.50)($41.50)
11/9/2018Q3 2018($21.00)($20.75)+$0.25($20.00)
8/14/2018Q2 2018($15.75)($17.75)($2.00)($17.75)
5/15/2018Q1 2018($10.00)($10.25)($0.25)($10.25)
3/19/2018Q4 2017($12.50)($27.50)($15.00)($27.50)
10/31/2017Q3 2017($40.00)($35.00)+$5.00($35.00)
8/7/2017Q2 2017($47.50)($35.00)+$12.50($35.00)
5/9/2017Q1 2017($110.00)($35.00)+$75.00($35.00)
2/27/2017Q4 2016($90.00)($185.00)($95.00)($185.00)
11/7/2016Q3 2016($102.50)($102.50)($102.50)
8/8/2016Q2 2016($120.00)($120.00)($120.00)
5/9/2016Q1 2016($90.00)($90.00)($90.00)
3/21/2016Q4 2015($192.50)($192.50)($192.50)
11/17/2015Q3 2015($100.00)($100.00)($100.00)
(Earnings results data provided by Zacks Investment Research)












Qualigen Therapeutics (NASDAQ:QLGN) Earnings Frequently Asked Questions

When is Qualigen Therapeutics's earnings date?

Qualigen Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 21st, 2022 based off last year's report dates. Learn more on QLGN's earnings history

Did Qualigen Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Qualigen Therapeutics (NASDAQ:QLGN) reported ($0.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.20) by $0.10. Learn more on QLGN's earnings details

How much profit does Qualigen Therapeutics generate each year?

Qualigen Therapeutics (NASDAQ:QLGN) has a recorded net income of -$1.67 million. QLGN has generated $0.00 earnings per share over the last four quarters.

This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.